Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 517 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sepsis Clear all

Conditions: Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)
Interventions: 5hmC Biomarker, Venetoclax, Decitabine 20 mg/m²/day for 5 days, Azacitidine (AZA), Cytarabine (Ara-C), Anthracycline; Diagnostic Test · Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
Interventions: AI-PERSONALIZED CLINICAL DECISION SUPPORT; Other
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 300,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Sepsis, Disseminated Intravascular Coagulation
Interventions: Not listed
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Not listed
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atrophy, Sepsis, Weakness
Interventions: Not listed
Lead sponsor: Gregory A. Schmidt; Other
Eligibility: 18 Years to 99 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome (MODS)
Interventions: Anakinra, Placebo; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 1 Day to 17 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 32
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 28 more

Conditions: Sepsis, Community Acquired Pneumonia (CAP)
Interventions: OPT101, Placebo; Drug · Other
Lead sponsor: Op-T LLC; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Septic Shock
Interventions: L-Carnitine, Normal Saline; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Jackson, Mississippi • Charlotte, North Carolina

Conditions: Kidney Failure, Chronic, Catheter-Related Infections
Interventions: Neutrolin, Heparin; Drug
Lead sponsor: CorMedix Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more

Conditions: Critical Illness, Sepsis, Acute Respiratory Failure (ARF), Multi-organ Failure, Acute Kidney Injury, Delirium Confusional State, Shock
Interventions: Point-of-care large language model decision support (ChatGPT-5); Other
Lead sponsor: MetroWest Artificial Intelligence Research Workgroup; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Framingham, Massachusetts

Conditions: Enterovirus Infection
Interventions: Placebo, Pleconaril; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 0 Days to 15 Days
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 24
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Adenovirus, Anesthesia, Anxiety, Anxiolysis, Autism, Autistic Disorder, Bacterial Meningitis, Bacterial Septicemia, Benzodiazepine, Bipolar Disorder, Bone and Joint Infections, Central Nervous System Infections, Convulsions, Cytomegalovirus Retinitis, Early-onset Schizophrenia Spectrum Disorders, Epilepsy, General Anesthesia, Gynecologic Infections, Herpes Simplex Virus, Infantile Hemangioma, Infection, Inflammation, Inflammatory Conditions, Intra-abdominal Infections, Lower Respiratory Tract Infections, Migraines, Pain, Pneumonia, Schizophrenia, Sedation, Seizures, Skeletal Muscle Spasms, Skin and Skin-structure Infections, Treatment-resistant Schizophrenia, Urinary Tract Infections, Withdrawal, Sepsis, Gram-negative Infection, Bradycardia, Cardiac Arrest, Cardiac Arrhythmia, Staphylococcal Infections, Nosocomial Pneumonia, Neuromuscular Blockade, Methicillin Resistant Staphylococcus Aureus, Endocarditis, Neutropenia, Headache, Fibrinolytic Bleeding, Pulmonary Arterial Hypertension, CMV Retinitis, Hypertension, Chronic Kidney Diseases, Hyperaldosteronism, Hypokalemia, Heart Failure, Hemophilia, Heavy Menstrual Bleeding, Insomnia
Interventions: The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:; Drug
Lead sponsor: Daniel Benjamin; Other
Eligibility: Up to 21 Years
Enrollment: 3,520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 43
States / cities: Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more

Conditions: Sepsis, Hyperglycemia, Critical Illness
Interventions: Not listed
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 5 Years to 19 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Septic Shock
Interventions: MR imaging; Diagnostic Test
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 3 Years to 18 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Septic Shock
Interventions: LB1148, Placebo; Drug
Lead sponsor: Leading BioSciences, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 26
States / cities: Mobile, Alabama • Fresno, California • Long Beach, California + 23 more

Conditions: Bacteremia, Candidemia
Interventions: RaPID/BSI Test; Diagnostic Test
Lead sponsor: HelixBind, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Marlborough, Massachusetts

Conditions: Sepsis
Interventions: Code Sepsis protocol (full implementation); Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 180,402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: Murray, Utah • Provo, Utah • St. George, Utah

Conditions: Sepsis, Coagulopathy
Interventions: BAY3389934; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Sepsis
Interventions: Not listed
Lead sponsor: Karius, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Sepsis
Interventions: heparin; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Necrotizing Pancreatitis
Interventions: Using ABTHERA Advance without a Wittmann Patch; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 22 Years and older
Enrollment: 3 participants
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Sepsis
Interventions: sPLA2 Inhibitor; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 60
States / cities: Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 57 more

Conditions: Sepsis
Interventions: Simvastatin, Identical-appearing placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sepsis, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: ALT-836, Placebo; Drug
Lead sponsor: Altor BioScience; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 20
States / cities: Los Angeles, California • Sacramento, California • Stanford, California + 15 more

Conditions: Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Interventions: Best Practice, Biospecimen Collection, Cytarabine, Electronic Health Record Review, Placebo Administration, Xylitol-containing Oral Wipe; Other · Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 25 Years
Enrollment: 556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 39
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Madera, California + 35 more

Search by objective public record fields.

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

Safe and Explainable AI

Thrombin Generation and Thromboelastography in Non-overt DIC

Muscle Atrophy in Sepsis

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

L-Carnitine Administration in Early Sepsis

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

Point-of-Care AI Assistance and Critical Care Outcomes: A Randomized Trial

Pleconaril Enteroviral Sepsis Syndrome

Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care

Gluconeogenesis Rates and Its Precursors in Pediatric Sepsis

Neuroimaging and Neuromonitoring in Critically Ill Children With Sepsis

Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148

Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood

Effects of Code Sepsis Implementation on Emergency Department (ED) Sepsis Care

A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy

SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay

Safety of Heparin in Patients With Septic Shock

ABTHERA ADVANCE™ Use Without Wittman Patch

A Phase IIb Study to Determine the Efficacy and Safety of the Study Drug in Patients With Severe Sepsis

Statins for the Early Treatment of Sepsis

Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia